Integrative Hormone Health, Metabolic Resilience, and Prostate Risk: An Evidence-Based Guide

Abstract

In this educational post, I walk you through the practical, physiology-first management of hormone health—with a special focus on sex hormone–binding globulin (SHBG), polycystic ovary syndrome (PCOS), insulin resistance, prostate-specific antigen (PSA) interpretation, and dehydroepiandrosterone (DHEA). Drawing on modern evidence-based methods and the latest work from leading researchers, I explain why and how these biomarkers change before standard markers do, how metabolic dysfunction shapes sex hormones, and how to interpret PSA beyond a single threshold. I also share clinical observations from my practice of integrative chiropractic care—where structural optimization, autonomic regulation, and gut-focused functional medicine work together to normalize endocrine signaling. By the end, you will understand why SHBG is a metabolic barometer, how to personalize PCOS interventions, when to order a free PSA and a 3T multiparametric MRI, and how to use DHEA strategically to restore neuroendocrine balance.

Introduction: Bringing Physiology to the Forefront

As a clinician trained across chiropractic, advanced practice nursing, and functional medicine, my goal is to connect dots that are often siloed—metabolism, hormones, neuroendocrine signaling, musculoskeletal integrity, and autonomic tone. In practice and in the literature, the throughline is clear: metabolic signals regulate sex hormone availability, receptor sensitivity, and downstream symptoms long before traditional markers (such as A1C) fully emerge (Ding et al., 2009; Laughlin et al., 2004).

I show you how I translate this science into stepwise care. I cover:

• Why a low SHBG is a red flag for metabolic dysfunction and insulin resistance.
• How to phenotype and treat PCOS—including “lean” PCOS and atypical presentations.
• How to interpret PSA using percent-free PSA and velocity, and when to order a 3T multiparametric prostate MRI.
• How and why DHEA impacts libido, mood, cognition, and skin, and how to dose it safely.
• Where integrative chiropractic care—posture, mobility, vagal tone, and gut-brain axis—fits into endocrine recovery.

I also reference and document case patterns I commonly see across my platforms, including my clinical insights published at Chiropracticscientist.com and professional notes on LinkedIn.

Key Concept 1: SHBG Is a Metabolic Barometer, Not a Target to Suppress

• What SHBG does: Sex hormone–binding globulin (SHBG) is a glycoprotein produced primarily by the liver that binds sex steroids—especially androgens such as testosterone—with higher affinity than estrogens (Rosner et al., 2010). By binding, SHBG regulates the proportion of free (bioavailable) hormones that can access cell receptors.
• Why binding matters physiologically: Hormones crossing the cell membrane and docking to their receptors initiate intracellular signaling; the bound fraction in plasma serves as a reserve that maintains stability. A common misconception is that high SHBG is “dangerous because it lowers free testosterone. In reality, chronically low SHBG is strongly associated with insulin resistance, metabolic syndrome, and cardiometabolic risk (Ding et al., 2009; Lakshman et al., 2010).

Clinical takeaway:

• Low SHBG is a predictive marker of metabolic dysfunction. In many patients, declines in SHBG precede A1C elevation, flagging hepatic insulin signaling and inflammatory load (Ding et al., 2009).
• Medications and physiological factors that increase SHBG Include Estrogen therapy, oral contraceptives, moderate alcohol consumption, and leaner, insulin-sensitive states (Sutton-Tyrrell et al., 2005). That rise is often protective, reflecting improved liver health and insulin signaling.

What to do when SHBG is low:

• Do not aim to “lower SHBG.” Instead, restore insulin sensitivity and hepatic metabolic integrity through:
  • Nutrition: low-glycemic, anti-inflammatory dietary patterns; adequate protein and fiber; polyphenols (e.g., berries, green tea) to improve insulin signaling (Esposito et al., 2004).
  • Movement: resistance training and brisk aerobic exercise to increase GLUT4 translocation and improve hepatic fat metabolism (Cortez-Cooper et al., 2005).
  • Sleep and stress: normalize cortisol rhythms and vagal tone; chronic stress drops SHBG via hepatic effects (Björntorp, 1997).
  • Integrative chiropractic care: spinal and pelvic alignment to reduce nociceptive stress, enhance autonomic balance, and support gut-brain axis regulation—improving inflammatory tone and indirectly raising SHBG by stabilizing insulin signaling. In my clinic, consistent thoracic and lumbopelvic mobilization combined with diaphragmatic breathing improves heart rate variability and reduces cravings, a practical marker of sympathetic downshift (Jimenez, clinical observation).

Why receptor saturation sometimes matters:

• When SHBG is high, raising total testosterone can saturate androgen receptors, ensuring adequate free testosterone remains available for symptom relief (Morgentaler & Traish, 2009). This is why some nutraceuticals, such as Shilajit (standardized fulvic acid complexes), may improve perceived energy and androgenic tone in certain patients; however, data are mixed, and product purity varies. Clinical use should be personalized, monitored, and integrated with metabolic rehabilitation.

Key Concept 2: PCOS Is Heterogeneous—Phenotype, Don’t Generalize

PCOS is one of the most common endocrine disorders in women, yet it is frequently missed because it spans multiple phenotypes. The Rotterdam criteria require two of three features: oligo- or anovulation, clinical/biochemical hyperandrogenism, and polycystic ovarian morphology (ESHRE/ASRM, 2004).

• Classic phenotype: Obesity, hirsutism, acne, irregular or heavy menses.
• Atypical/lean phenotype: Normal BMI, minimal hirsutism, but elevated LH: FSH ratio (often >2:1), high free testosterone or DHEA-S, menstrual pain, or irregular cycles. Many of these patients have gut dysbiosis and insulin signaling abnormalities without overt hyperglycemia (Qi et al., 2021).

Physiology linking gut and ovaries:

• Hyperinsulinemia suppresses hepatic SHBG production, raising free androgens.
• Insulin and IGF-1 increase ovarian theca cell androgen synthesis, elevating testosterone and DHEA-S (Diamanti-Kandarakis & Dunaif, 2012).
• Dysbiosis and endotoxin leakage (LPS) amplify TLR4/NF-?B inflammation, worsening insulin resistance and ovarian steroidogenesis (Qi et al., 2021).
• High LH: FSH ratios reflect altered hypothalamic-pituitary signaling and favor androgen production.

Case patterns I see:

• Young, athletic women with severe dysmenorrhea and irregular cycles but no acne or hirsutism. Labs show LH triple FSH, free testosterone above range, normal-to-low SHBG, and high DHEA-S. In these cases, the gut-insulin axis is the driver. In my practice, GI mapping often reveals bacterial overgrowth, low butyrate producers, or Candida, with concurrent micronutrient imbalances (Jimenez, clinical observation).

Stepwise evaluation:

• Hormone panel: Total and free testosterone, SHBG, DHEA-S, LH, FSH, estradiol, progesterone (timed to cycle).
• Metabolic panel: Fasting insulin, glucose, HOMA-IR, lipids (look for high triglycerides, low HDL), and hs-CRP.
• Gut panel: stool testing for microbiome balance, pathobionts, secretory IgA, calprotectin, short-chain fatty acids.

Treatment pillars:

• Lower insulin load:
  • Metformin: titrate from 500 mg nightly to 1,500–2,000 mg/day as tolerated; GI effects reflect improved intestinal incretin signaling and typically diminish (American Diabetes Association [ADA], 2024).
  • GLP-1 receptor agonists (e.g., semaglutide, exenatide) in select cases—effective for weight reduction, insulin sensitivity, and androgen-related symptoms (Wilding et al., 2021).
• Anti-androgen symptom relief:
  • Spironolactone 100 mg/day for hirsutism and acne; blocks the androgen receptor and reduces LH/testosterone, but does not treat root causes (Brown et al., 2009).
  • Topical spironolactone and anti-androgenic OCPs (e.g., drospirenone-containing Yaz/Yasmin) for acne/hirsutism when contraception is desired (Azziz et al., 2016).
• Restore ovulation and cycles:
  • Normalize insulin signaling, reduce inflammation, and repair the gut barrier; ovulatory cycles can take up to 24 months to normalize after comprehensive care (Legro et al., 2014).
• Integrative chiropractic care:
  • Address lumbopelvic mechanics to relieve sacral and pelvic floor strain—improving uterine perfusion and autonomic balance. Thoracolumbar mobility and soft-tissue release reduce nociception-driven cortisol, thereby improving insulin sensitivity and cycle regularity (Jimenez, clinical observation).
  • Breathing and vagal tone drills—box breathing, humming, and cervical mobilization—help downshift the sympathetic drive and indirectly lower LH pulsatility via hypothalamic regulation.

Hormone therapy cautions:

• In insulin-resistant women with low SHBG, standard dosing of testosterone therapy can overshoot free testosterone and cause side effects. Start low and go slow (e.g., 50–80 mg implant/pellet equivalents, or low-dose transdermals), monitor SHBG, free T, and symptoms over 6–8 weeks (Wierman et al., 2014).

Fertility observations:

• I’ve managed multiple couples where gut repair, insulin normalization, micronutrient repletion (iron, iodine, vitamin D), and stress regulation restored ovulation after prolonged infertility—even in women well into their 30s. The timeline can be years, but the physiology is consistent: reduce insulin, raise SHBG, lower free androgen excess, cycles return, and fertility follows (Jimenez, clinical observation; Legro et al., 2014).

Key Concept 3: PSA Interpretation—Percent-Free PSA and Velocity Guide Action

The prostate-specific antigen (PSA) conversation is more nuanced than a single cutoff. PSA is specific to prostate tissue but not cancer-specific; benign prostatic hyperplasia (BPH), prostatitis, ejaculation, and manipulation can elevate PSA (Crawford et al., 2014).

Smarter PSA workflow:

• Total PSA with reflex percent-free PSA when total PSA >4 ng/mL.
• Interpretation:
  • Lower percent-free PSA implies a higher likelihood of cancer. For example:
    • <10%: high risk; consider urology referral and/or 3T multiparametric prostate MRI.
    • 10–20%: intermediate risk; treat suspected prostatitis if symptomatic and recheck PSA in ~3 months.
    • >20%: low risk; repeat in ~3 months (Catalona et al., 1998).
• PSA velocity matters:
  • Rapid change (e.g., from 0.9 to 2.9 within one year) suggests aggressive pathology; even if the absolute number is “normal,” velocity warrants imaging/urology input (Loeb et al., 2012).

Why 3T multiparametric prostate MRI:

• A 3 Tesla multiparametric MRI combines T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast to identify suspicious lesions with higher accuracy than ultrasound-guided biopsy alone (Barentsz et al., 2012).
• Most men prefer MRI, and radiologists can also identify acute/chronic prostatitis, helping to clarify benign causes of PSA bumps.

Practical pearls:

• Finasteride lowers total PSA by ~50% but does not change percent-free PSA; adjust total PSA interpretation accordingly (Crawford et al., 2014).
• Ejaculation and vigorous cycling can transiently raise total PSA; percent-free PSA is less impacted by such activities.
• Testosterone therapy: When PSA is healthy, and there is no significant BPH/suspicion, most guidelines allow testosterone replacement with routine monitoring; coordinate with urology if prior PSA fluctuation exists (Bhasin et al., 2018).

Where integrative chiropractic care helps:

• Chronic pelvic floor hypertonicity and lumbosacral dysfunction can mimic prostatitis symptoms and elevate stress-driven inflammation. Pelvic floor release, sacroiliac mobilization, and diaphragmatic training reduce pelvic congestion and discomfort, often making PSA retesting more interpretable (Jimenez, clinical observation).

Key Concept 4: DHEA—A Neurosteroid With Wide Clinical Reach

Dehydroepiandrosterone (DHEA) and DHEA-S decline with age beginning in the 30s. DHEA is synthesized in the adrenal cortex and in the central nervous system, acting as a neurosteroid with its own receptors and effects on mood, cognition, skin, and sexual function (Maninger et al., 2009).

Why DHEA matters even if testosterone is “normal”:

• Patients—especially women—with adequate total and free testosterone can still experience low libido, depressed mood, and anorgasmia if DHEA is low. DHEA impacts dopaminergic and GABAergic tone and has a high conversion potential to DHT in females, improving sexual arousal and orgasmic function in select cases (Arlt et al., 1999; Davis et al., 2013).

Physiologic effects:

• Modulates cell membrane fluidity, inflammation, vascular function, bone turnover, and skin integrity (Maninger et al., 2009).
• Lower DHEA/DHEA-S ratios correlate with higher all-cause mortality and more rapid cognitive decline in some populations (Weiss et al., 2011).

Dosing strategy:

• Start with comprehensive labs: DHEA-S, total/free testosterone, estradiol, progesterone, thyroid.
• If DHEA-S is in double digits for women or markedly low for men:
  • Compounded DHEA (preferred for purity/consistency): 5–10 mg/day for women; 20 mg/day for men; recheck levels in 6–8 weeks.
  • Over-the-counter DHEA in the U.S. varies in quality; if used, start at 25 mg/day and monitor closely.
• Avoid DHEA in women with PCOS or androgen-sensitive conditions, as many already have high DHEA-S.

Integrative chiropractic and DHEA:

• By attenuating sympathetic overdrive through spinal and soft-tissue techniques and breathwork, we reduce cortisol’s antagonism of DHEA production. Patients frequently report improved mood and libido after combining adrenal support, micronutrients (e.g., vitamin C, magnesium, B5), and structured mobility/breath training (Jimenez, clinical observation).

Putting It All Together: A Practical Care Map

• Assess the terrain:
  • Hormone panel: Total/free testosterone, SHBG, estradiol, progesterone, DHEA-S, LH/FSH.
  • Metabolic panel: Fasting insulin, glucose, HOMA-IR, lipids, hs-CRP, liver enzymes.
  • Gut panel: stool mapping; consider SIBO breath testing if indicated.
  • Men’s risk: Total PSA with reflex percent-free PSA when >4; note velocity changes; consider 3T multiparametric MRI for risk clarification.
• Build the base:
  • Diet: anti-inflammatory, low-glycemic, fiber-rich; prioritize protein, omega-3s, polyphenols.
  • Movement: resistance 2–3x/week; aerobic 150–300 min/week; mobility daily.
  • Sleep/stress: 7–9 hours; vagal tone drills and sunlight exposure.
  • Integrative chiropractic care: spinal alignment, pelvic mechanics, soft tissue release, breath training to normalize autonomic tone and reduce inflammatory signaling.
• Targeted therapies:
  • PCOS: Metformin or GLP-1 RAs, spironolactone for symptoms; consider OCPs when appropriate; prioritize gut repair and micronutrients; slow, cautious androgen therapy if needed with close monitoring.
  • Men’s hormones: personalize testosterone dosing only after PSA review; align with urology for any ambiguity.
  • Low DHEA symptoms: trial compounded DHEA with monitoring; avoid in high-androgen phenotypes.

Clinical Observations From My Practice

Across my patient population, the most predictable wins occur when I anchor care in physiology:

• Raising SHBG by restoring insulin sensitivity reliably reduces free androgen excess and improves acne/hirsutism without escalating anti-androgen therapy.
• Pelvic and thoracolumbar mobilization with breath training reduces menstrual pain and stabilizes cycles in women with dysautonomia-driven PCOS features.
• In men, percent-free PSA and velocity help prevent unnecessary biopsies; 3T mpMRI helps distinguish prostatitis from small focal lesions, simplifying follow-up.
• Correcting low DHEA resolves otherwise stubborn libido and mood complaints even when testosterone looks “good.”

The enduring message is this: align mechanics, metabolism, and mind, and the hormones follow.

---

References

• Catalona, W. J., Partin, A. W., Slawin, K. M., et al. (1998). Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA.
• Barentsz, J. O., Richenberg, J., Clements, R., et al. (2012). ESUR prostate MR guidelines 2012. European Radiology.
• Crawford, E. D., Ventii, K., Shore, N. D. (2014). Variability in PSA measurements: Impact on clinical decisions. Urology.
• Bhasin, S., Brito, J. P., Cunningham, G. R., et al. (2018). Testosterone therapy in men: Endocrine Society guideline. Journal of Clinical Endocrinology & Metabolism.
• Diamanti-Kandarakis, E., & Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocrine Reviews.
• ESHRE/ASRM. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction.
• Ding, E. L., Song, Y., Manson, J. E., et al. (2009). Sex hormone–binding globulin and risk of type 2 diabetes in women and men. New England Journal of Medicine.
• Lakshman, K. M., Bhasin, S., Araujo, A. B., et al. (2010). Sex hormone–binding globulin as a marker of metabolic health. Journal of Clinical Endocrinology & Metabolism.
• Laughlin, G. A., Barrett-Connor, E., & May, S. (2004). Sex hormone–binding globulin and hyperinsulinemia in older adults. Journal of Clinical Endocrinology & Metabolism.
• Legro, R. S., Arslanian, S. A., Ehrmann, D. A., et al. (2014). Diagnosis and treatment of PCOS in adolescents and adults. Journal of Clinical Endocrinology & Metabolism.
• Brown, J., Farquhar, C., Lee, O., et al. (2009). Spironolactone for hirsutism. Cochrane Database of Systematic Reviews.
• Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine.
• Qi, X., Yun, C., Sun, L., et al. (2021). Gut microbiota and PCOS. Frontiers in Endocrinology.
• Maninger, N., Wolkowitz, O. M., Reus, V. I., et al. (2009). Neurobiological and psychiatric effects of DHEA. CNS Drugs.
• Arlt, W., Callies, F., van Vlijmen, J. C., et al. (1999). Androgenic effects of DHEA in women. Journal of Clinical Endocrinology & Metabolism.
• Davis, S. R., Worsley, R., Miller, K. K., et al. (2013). Androgens and female sexual function. Journal of Sexual Medicine.
• Weiss, E. P., Villareal, D. T., Racette, S. B., et al. (2011). DHEA and aging: A randomized trial. Journal of the American Geriatrics Society.
• Cortez-Cooper, M. Y., Alvis, B. A., Black, C. E., et al. (2005). Aerobic exercise and insulin sensitivity. Hypertension.
• Esposito, K., Giugliano, D., & Giugliano, F. (2004). Mediterranean diet and insulin resistance. JAMA.
• Morgentaler, A., & Traish, A. (2009). Shifting the testosterone paradigm: The saturation model. European Urology.
• Loeb, S., Vickers, A., Roehl, K. A., et al. (2012). PSA velocity. European Urology.
• Rosner, W., Hryb, D. J., Khan, M. S., et al. (2010). SHBG physiology. Endocrine Reviews.
• Sutton-Tyrrell, K., Wildman, R. P., Matthews, K. A., et al. (2005). Sex hormones and cardiovascular risk. Journal of Clinical Endocrinology & Metabolism.
• Wierman, M. E., Arlt, W., Temperton, H., et al. (2014). Androgen therapy in women: Guidelines. Journal of Clinical Endocrinology & Metabolism.
• American Diabetes Association. (2024). Standards of Care in Diabetes—2024. Diabetes Care.